• 1
    Crimi E, Voltolini S, Troise C, Gianiorio P, Crimi P, Brusasco V et al. Local immunotherapy with Dermatophagoides product in asthma. J Allergy Clin Immunol 1991;87:721728.
  • 2
    Tari MG, Mancino M, Monti G. Immunotherapy by inhalation of allergen in powder in house dust allergic asthma: a double-blind study. J Investig Allergol Clin Immunol 1992;2:5967.
  • 3
    Bousquet J, Lockey RF, Malling H-J (Eds). WHO Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998;53(Suppl. 44):142.
  • 4
    Moller C, Dreborg S, Lanner A, Bjorksten B. Oral immunotherapy in children with rhinoconjunctivitis due to birch pollen allergy. Allergy 1986;41:271279.
  • 5
    Giovane AL, Bardare M, Passalacqua G, Ruffoni S, Scordamaglia A, Ghezzi E et al. A three-year double-blind placebo-controlled study with specific oral immunotherapy to Dermatophagoides: evidence of safety and efficacy in paediatric patients. Clin Exp Allergy 1994;24:5359.
  • 6
    Cooper PJ, Darbyshire J, Nunn AJ, Warner JO. A controlled trial of oral hyposensitization in pollen asthma and rhinitis in children. Clin Allergy 1984;14:541550.
  • 7
    Oppenheimer J, Areson JG, Nelson HS. Safety and efficacy of oral immunotherapy with standardized cat product. J Allergy Clin Immunol 1994;93:6167.
  • 8
    Mosbech H, Dreborg S, Madsen F, Ohlsson H, Stahl Skov P, Taudorf E et al. High dose grass pollen tablets used for hyposensitization in hay fever patients. A one-year double blind placebo-controlled study. Allergy 1987;42:451455.
  • 9
    Canonica GW, Passalacqua G. Noninjection routes for immunotherapy. J Allergy Clin Immunol 2003;111:437448.
  • 10
    Nickelsen JA, Goldstein S, Mueller U, Wypych J, Reisman RE, Arbesman CE. Local intranasal immunotherapy for ragweed allergic rhinitis: clinical response. J Allergy Clin Immunol 1981;68:3340.
  • 11
    Welsh PW, Butterfield JH, Yunginger JM, Agarwal MK, Gjeich GJ. Allergen-controlled study of intranasal immunotherapy for ragweed hay fever. J Allergy Clin Immunol 1983;71:454460.
  • 12
    Passalacqua G, Albano M, Pronzato C, Riccio AM, Scordamaglia A, Falagiani P et al. Long-term follow-up of nasal immunotherapy to Parietaria: clinical and local immunological effects. Clin Exp Allergy 1997;27:904908.
  • 13
    Brown JL, Frew AJ. The efficacy of oromucosal immunotherapy in respiratory allergy. Clin Exp Allergy 2001;31:810.
  • 14
    Malling HJ. Is sublingual immunotherapy clinically effective? Curr Opin Allergy Clin Immunol 2002;2:523531.
  • 15
    Nelson HS. Advances in upper airway disease and allergen immunotherapy. J Allergy Clin Immunol 2003;111:0s793-s798.
  • 16
    Khinchi MS, Poulsen LK, Carat F, André C, Hansen AB, Malling H-J. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 2004;59:4553.
  • 17
    Wilson DR, Torres  Lima M, Durham SE. Sublingual immunotherapy for allergic rhinitis: systemic review and meta-analysis. Allergy 2005;60:412.
  • 18
    André C, Perrin-Fayolle M, Grosclaude M, Couturier P, Basset D, Cornillon J et al. A double-blind placebo-controlled evaluation of sublingual immunotherapy with a standardized ragweed product in patients with seasonal rhinitis. Evidence for a dose–response relationship. Int Arch Allergy Immunol 2003;131:111118.
  • 19
    Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108:S147336.
  • 20
    Grosclaude M, Bouillot P, Alt R, Leynadier F, Scheinmann P, Rufin P et al. Safety of various dosage regimens during induction of sublingual immunotherapy. A preliminary study. Int Arch Allergy Immunol 2002;129:248253.
  • 21
    Lombardi C, Giargioni S, Melchiorre A, Tiri A, Falagiani P, Canonica GW et al. Safety of sublingual immunotherapy with monomeric allergoid in adults: multicenter post-marketing surveillance study. Allergy 2001;56:989992.
  • 22
    Di Rienzo V, Marcucci F, Puccinelli P, Parmiani S, Frati F, Sensi L et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy 2003;33:206210.
  • 23
    Mungan D, Misirligil Z, Gürbüz L. Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma – a placebo controlled study. Ann Allergy Asthma Immunol 1999;82:485490.
  • 24
    Bernardis P, Agnoletto M, Puccinelli P, Parmiani S, Pozzan M. Injective versus sublingual immunotherapy in Alternaria tenuis allergic patients. J Invest Allergol Clin Immunol 1996;6:5562.
  • 25
    Quirino T, Iemoli E, Siciliani E, Parmiani S, Milazzo F. Sublingual versus injective immunotherapy in grass pollen allergic patients: a double-blind, (double-dummy) study. Clin Exp Allergy 1996;26:12531261.
  • 26
    Novembre E, Galli E, Landi F, Gaffarelli C, Pifferi M, De Marco E et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004;114:851857.
  • 27
    Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical efficacy and more. Allergy 2004;59:12051210.
  • 28
    Scheinmann P, Ponvert C, Rufin P, De Blic J. Immunotherapy in young children. In: LockeyRF, BukantzSC, BousquetJ, editors. Allergens and allergen immunotherapy. New York: Marcel Dekker, 2004:567583.
  • 29
    Sopo SM, Macchiaiolo M, Zorzi G, Tripodi S. Sublingual immunotherapy in asthma and rhinoconjunctivitis; systematic review of paediatric literature. Arch Dis Child 2004;89:620624.